Arovella Therapeutics ASX: ALA
Debora Barton serves as the Chief Medical Officer at Full-Life Technologies, a global radiotherapeutics company specializing in radiopharmaceuticals, since May 2025. In addition, Debora is a member of the Board of Advisors at Deverra Therapeutics, contributing to the development of off-the-shelf cellular immunotherapies, and participates on the Clinical Advisory Board of Arovella Therapeutics, focusing on iNKT cell therapy in oncology. As a Non-Executive Director (NED) board member at Arovella Therapeutics, Debora also provides insights in executive roles at NeoGenomics Laboratories and ANIM8 LLC, the latter being a consultancy for oncology pharmaceutical and biotechnology sectors. Debora holds an MD in Internal Medicine and Medical Oncology from Universidade Federal de São Paulo and completed an Executive Education program in Women in Leadership at Columbia Business School.
This person is not in any teams
This person is not in any offices
Arovella Therapeutics ASX: ALA
Biotechnology, cell therapy, oncology, iNKT cell therapy, invariant natural killer T (iNKT) cell therapy platform, blood cancers, solid tumours, gastric & pancreatic cancers.